References
- Querfurth HW, LaFerla FM. Alzheimer’s disease. N. Engl. J. Med.362(4), 329–344 (2010).
- Budson AE, Solomon PR. Memory Loss: A Practical Guide for Clinicians. Elsevier Inc., Philadelphia, PA, USA (2011).
- Sperling RA, Aisen PS, Beckett LA et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement.7(3), 280–292 (2011).
- Reiman EM, Chen K, Alexander GE et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer’s dementia. Proc. Natl Acad. Sci. USA101(1), 284–289 (2004).
- Filippini N, Ebmeier KP, MacIntosh BJ et al. Differential effects of the APOE genotype on brain function across the lifespan. Neuroimage54(1), 602–610 (2011).
- Fleisher AS, Podraza KM, Bangen KJ et al. Cerebral perfusion and oxygenation differences in Alzheimer’s disease risk. Neurobiol. Aging30(11), 1737–1748 (2009).
- Shaw P, Lerch JP, Pruessner JC et al. Cortical morphology in children and adolescents with different apolipoprotein E gene polymorphisms: an observational study. Lancet Neurol.6(6), 494–500 (2007).
- Acosta-Baena N, Sepulveda-Falla D, Lopera-Gomez CM et al. Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer’s disease: a retrospective cohort study. Lancet Neurol.10(3), 213–220 (2011).
- Fox NC, Warrington EK, Stevens JM, Rossor MN. Atrophy of the hippocampal formation in early familial Alzheimer’s disease. A longitudinal MRI study of at-risk members of a family with an amyloid precursor protein 717Val-Gly mutation. Ann. NY Acad. Sci.777, 226–232 (1996).
- Ridha BH, Barnes J, Bartlett JW et al. Tracking atrophy progression in familial Alzheimer’s disease: a serial MRI study. Lancet Neurol.5(10), 828–834 (2006).
- Mondadori CR, Buchmann A, Mustovic H et al. Enhanced brain activity may precede the diagnosis of Alzheimer’s disease by 30 years. Brain129(Pt 11), 2908–2922 (2006).
- Quiroz YT, Budson AE, Celone K et al. Hippocampal hyperactivation in presymptomatic familial Alzheimer’s disease. Ann. Neurol.68(6), 865–875 (2010).
- Ringman JM, O’Neill J, Geschwind D et al. Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer’s disease mutations. Brain130(Pt 7), 1767–1776 (2007).
- Bobes MA, Garcia YF, Lopera F et al. ERP generator anomalies in presymptomatic carriers of the Alzheimer’s disease E280A PS-1 mutation. Hum. Brain Mapp.31(2), 247–265 (2010).
- Quiroz YT, Ally BA, Celone K et al. Event-related potential markers of brain changes in preclinical familial Alzheimer disease. Neurology77(5), 469–475 (2011).
- Reiman EM, Langbaum JB, Tariot PN. Alzheimer’s prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible. Biomark. Med.4(1), 3–14 (2010).
- Reiman EM, Langbaum JBS, Fleisher AS et al. Alzheimer’s Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J. Alzheimers Dis.25(Suppl. 3), 293–301 (2011).